ChartRow logo
Data provided bySource: Twelve Data
ARGX
$927.21+3.63%
as of close, Nov 6, 2026
☾ AH $927.21 +3.63%
Share this page

ARGX — argenx SE American Depositary Shares price, chart and key statistics

Technical analysis2
Overlay lines0
Addendum charts0
Data provided bySource: Twelve Data
What would $1,000 invested in ARGX be worth today? →
ARGX returns: By year · By month · By week · Trailing

Price data

Price
$927.21
YTD price return
+10.26%
YTD total return
+10.26%
Market cap
57.4B
Enterprise value
53.9B
Shares outstanding
61.9M
52W low
$661.85
52W high
$1,072.75
From 52W high
-13.57%
From 52W low
+40.09%
52W range
65%$662–$1073
Beta
0.45

Volume

Rel volume
0.82×
30D volume
458.3K
30D $ vol
400.2M

Fundamentals

EPS (ttm)
$19.57
FCF (ttm)
679M
FCF/share
$10.97
Book value/share
$118.34
ROE
17.64%
ROA
14.88%
Current ratio
5.23

Growth (CAGR, ttm) · 10Y

Sales
+254.72%-4.85%+6.99%n/a
Net income
+55.15%n/an/an/a
Shares
+1.85%+3.76%+5.40%+14.62%

Per-share growth (CAGR, ttm) · 10Y

EPS
+53.17%n/an/an/a
Sales/share
+231.94%-11.54%-3.16%n/a
Book value/share
+30.80%+32.56%+27.45%+46.60%
Price
+8.96%+23.43%+23.63%+47.75%
Total return
+8.96%+23.43%+23.63%+47.75%

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)
47.4×
Fwd P/E
29.0×
P/B (mrq)
7.8×
P/FCF (ttm)
84.5×
FCF yield (ttm)
1.18%
Buyback yield (realized, 1y)
-1.85%
Shareholder yield (realized, 1y)
-1.85%
Buyback yield (cash, ttm)
0.00%
Shareholder yield (cash, ttm)
0.00%

Vs own 10Y history

P/S
86th
P/B
65th

Bar = where today’s multiple sits in ARGX’s own 10-year range:near a decade-low (cheap)→mid-range→near a decade-high (rich).

Performance · price returntotal return · as of 2026-11-06#

Data provided bySource: Twelve Data
1D
+3.63%
5D
+3.85%
1M
-0.36%
3M
+5.93%
YTD
+10.26%
1Y
+8.95%
5Y
+188.92%
1D
+3.63%
5D
+3.85%
1M
-0.36%
3M
+5.93%
YTD
+10.26%
1Y
+8.95%
5Y
+188.92%

Fundamentals#

Revenue

5Y CAGR +7.0%5Y CAGR +7.0%
— FY25
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25

No quarters filed for this figure.

Operating income

5Y n/m5Y n/m
$1.1B FY25
FY17FY18FY19FY20FY21FY22FY23FY24FY25

No quarters filed for this figure.

EPS (diluted)

5Y n/m5Y n/m
$19.57 FY25
FY19FY20FY21FY22FY23FY24FY25

No quarters filed for this figure.

Free cash flow

5Y n/m10Y n/m
$679M FY25
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25

FY25: operating cash flow $685.2M, capex −$6.2M

No quarters filed for this figure.

Shares (diluted)

5Y +45.4%5Y +45.4%
66M FY25
FY19FY20FY21FY22FY23FY24FY25

No quarters filed for this figure.

Net income

5Y n/m10Y n/m
$1.3B FY25
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25

No quarters filed for this figure.

Full ARGX financials →

argenx SE American Depositary Receipt is an American depositary receipt representing shares of argenx SE, a Netherlands-based biopharmaceutical company focused on developing and commercializing antibody-based therapies for severe autoimmune and neuromuscular diseases. The company’s current portfolio centers on immunology medicines, including treatments for generalized myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy. argenx also advances a broader pipeline of differentiated antibody therapeutics built on its proprietary Simple Antibody platform, which supports research across autoimmune and other specialty disease areas. As an ADR, it gives U.S. market participants a way to access argenx’s underlying equity exposure through a familiar U.S.-traded security. The asset is closely tied to the global biotechnology and healthcare markets, where demand for specialized biologic therapies continues to shape commercial and clinical activity.

Amsterdam, Netherlands·1,599 employees·Biotechnology·argenx.com·As of Oct 28, 2026

Recent filings#

No earnings release, press release or insider trade outside a 10b5-1 plan in the last 120 days.

All filings and insider trades →

ETFs holding ARGX#

11 of the 193 ETFs ChartRow carries live hold ARGX. The 8 largest positions, by the weight each fund filed in its latest SEC N-PORT report (Jun 26 to Aug 26).

FundNameFiled weight
EWKiShares MSCI Belgium ETF16.9%
IBBiShares Biotechnology ETF3.8%
VGKVanguard FTSE Europe ETF0.3%
EFAiShares MSCI EAFE ETF0.2%
VEAVanguard FTSE Developed Markets ETF0.2%
VEUVanguard FTSE All-World ex-US ETF0.1%
VXUSVanguard Total International Stock ETF0.1%
URTHiShares MSCI World ETF0.1%
TickerName1M1D
LLYEli Lilly and Company+16.98%-0.79%
JNJJohnson & Johnson+8.42%+1.43%
ABBVAbbVie Inc.+9.23%+1.07%
MRKMerck & Co. Inc.+3.37%-0.14%
UNHUnitedHealth Group Incorporated Common Stock (DE)+4.74%-0.40%
NVSNovartis AG+15.46%+0.38%
TMOThermo Fisher Scientific Inc.+5.81%+2.63%
AMGNAmgen Inc.+14.36%+0.03%